A Novel Telomerase-Specific Gene Therapy: Gene Transfer of Caspase-8 Utilizing the Human Telomerase Catalytic Subunit Gene Promoter
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Apoptosis is a genetically encoded cell death process and is a pathway that may be disrupted in tumor cells. Therefore, therapies that restore the ability to undergo apoptosis are promising for the treatment of tumor cells. We have demonstrated that the transfer of apoptosis-inducible genes inhibits the growth of tumors in vitro and in vivo through induction of apoptosis. However, to restrict induction of apoptosis to tumor cells, we need to explore a tumor-specific expression system of these genes. In the present study, we developed the telomerase-specific transfer system of apoptosis-inducible genes, utilizing the promoter of the human telomerase catalytic subunit (hTERT) gene. Approximately 90% of tumors have telomerase activity whereas most normal cells do not express the activity. These observations indicate that telomerase is a particularly attractive target for the tumor-specific expression system of vectors. We demonstrate here that by using the hTERT promoter-driven caspase-8 expression vector (hTERT/caspase-8), apoptosis is restricted to telomerase-positive tumor cells of wide range, and is not seen in normal fibroblast cells without telomerase activity. Furthermore, treatment of subcutaneous tumors in nude mice with the hTERT/caspase-8 construct inhibited tumor growth significantly because of induction of apoptosis (p < 0.01). The telomerase-specific expression of apoptosis-inducible genes afforded by the hTERT promoter, therefore, may be a novel and promising targeting approach for the treatment of tumors with telomerase activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of telomeres
Blackburn, E. H. (1991) · Nature · doi:10.1038/350569a0 · Cited by 3,596
Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81266-0 · Cited by 3,046 · cited 3×
“…phosphate buffer (pH 7.5)] at 37°C for 3 hr. Cells were visualized by phase-contrast microscopy to detect morphological alterations typical of adherent cells undergoing apoptosis, i.e., rounded appearance or condensed nucleus as described previously (Muzio et al. , 1996; Kondo et al. , 1998a,b).”
InfluentialTelomerase Catalytic Subunit Homologs from Fission Yeast and Human
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., & Cech, T. R. (1997) · Science · doi:10.1126/science.277.5328.955 · Cited by 2,256
The RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · cited 1×
“Three components of the human telomerase have been identified: the RNA component (hTR) (Feng et al. , 1995), the telomerase-asso ciated protein (TEP1) (Harrington et al. , 1997; Nakayama et al. , 1997), and the telomerase catalytic subunit or telomerase reverse transcriptase (hTERT) (Meyerson et…”
Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80538-3 · Cited by 1,784 · cited 3×
“…have been identified: the RNA component (hTR) (Feng et al. , 1995), the telomerase-asso ciated protein (TEP1) (Harrington et al. , 1997; Nakayama et al. , 1997), and the telomerase catalytic subunit or telomerase reverse transcriptase (hTERT) (Meyerson et al. , 1997; Nakamura et al. , 1997).”
Chen, X., Ko, L. J., Jayaraman, L., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.19.2438 · Cited by 735
Cited by
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., & Kondo, S. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401359 · Cited by 986
Self-citationHuman Telomerase and Its Regulation
Cong, Y.-S., Wright, W. E., & Shay, J. W. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.3.407-425.2002 · Cited by 898
Telomerase therapeutics for cancer: challenges and new directions
Shay, J. W., & Wright, W. E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2081 · Cited by 432
Natural and pharmacological regulation of telomerase
Mergny, J.-L. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.4.839 · Cited by 352
Metadata
- Authors
- Koga, S., Hirohata, S., Kondo, Y., Komata, T., Takakura, M., Inoue, M., Kyo, S., & Kondo, S.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2000-07
- Volume
- 11
- Issue
- 10
- Pages
- 1397-1406
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2108967610
- Cited by
- 112
- References
- 6
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Telomerase-Specific Gene Therapy: Gene Transfer of Caspase-8 Utilizing the Human Telomerase Catalytic Subunit Gene Promoter. https://app.cochat.ai/papers/10.1089/10430340050057477
- The paper
- Koga, S., Hirohata, S., Kondo, Y., Komata, T., Takakura, M., Inoue, M., Kyo, S., & Kondo, S. (2000). A Novel Telomerase-Specific Gene Therapy: Gene Transfer of Caspase-8 Utilizing the Human Telomerase Catalytic Subunit Gene Promoter. Human Gene Therapy. https://doi.org/10.1089/10430340050057477
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.